A prostate cancer survivor with multiple treatments with ADT, abiraterone, chemotherapy, and PSA up and down over...

Clinical Trial Guidance for Your Prostate Cancer Journey

Thank you for sharing your detailed medical history. Your situation—with a Gleason score of 8 (Grade Group 4) and a history of multiple treatments including ADT, abiraterone, and chemotherapy—represents advanced disease that requires careful consideration of next-step options. Let me help you understand what to look for in clinical trials and how to approach this search.

Understanding Your Current Status

Your PSA of 0.70 ng/mL suggests your current treatment regimen is providing disease control, which is encouraging. However, given your treatment history (ADT, abiraterone, chemotherapy), your care team is likely monitoring closely for any signs of progression or resistance to hormone therapy.

According to NCCN Guidelines for Advanced-Stage Prostate Cancer, patients with your treatment history may benefit from:

• Continued ADT (androgen deprivation therapy) as a backbone
• Additional targeted or novel therapies depending on specific biomarkers
• Clinical trials investigating newer combination approaches

What Clinical Trials Might Be Relevant for You

1) Biomarker-Driven Trials

Given your extensive treatment history, clinical trials focusing on specific mutations are particularly important:

BRCA/DNA Repair Mutations:

• If you have BRCA1/BRCA2 or other DNA repair gene mutations, trials investigating PARP inhibitors (like niraparib) combined with hormone therapy may be relevant
• According to NCCN Guidelines, patients with BRCA mutations have specific treatment pathways that include combination approaches

PSMA-Targeted Therapies:

• PSMA (prostate-specific membrane antigen) is a protein on prostate cancer cells that can be targeted
• PSMA-directed therapies and imaging are increasingly available in clinical trials
• These may be particularly relevant given your advanced disease and treatment history

2) Immunotherapy Trials

• Sipuleucel-T (Provenge) and other immunotherapy approaches are being studied in combination with standard treatments
• According to NCCN Guidelines, immunotherapy options exist for patients with limited metastatic disease

3) Novel Hormone Therapy Combinations

• Trials combining newer androgen receptor-targeted agents with other mechanisms
• Given your abiraterone exposure, trials investigating different sequencing or combinations may be appropriate

How to Find Trials in Israel

Critical Step: Finding trials available in your location is essential. Here are your best resources:

1. ClinicalTrials.gov (https://clinicaltrials.gov/)

   • Filter by: "Prostate Cancer" + "Israel" + your specific criteria
   • You can search by disease, location, and trial phase

2. Israeli Cancer Research Organizations:

   • Sheba Medical Center (Tel Hashomer) - major cancer research center
   • Hadassah Medical Center - active in prostate cancer trials
   • Tel Aviv Sourasky Medical Center
   • These institutions often have dedicated clinical trial coordinators

3. European Trial Databases:

   • Since Israel participates in European research networks, check EORTC (European Organisation for Research and Treatment of Cancer) trials
   • Many European trials may be accessible to Israeli patients

4. Your Oncology Team:

   • Your current care team should have access to trial databases specific to Israel
   • They can identify which trials match YOUR specific biomarkers and treatment history

Questions to Ask Your Care Team About Clinical Trials

Before enrolling in any trial, ask these specific questions:

1. "Are there trials available in Israel that match my specific situation—Gleason 8, GG4, with my treatment history?"

2. "Have I been tested for BRCA mutations or other DNA repair gene mutations? If not, should I be, especially for trial eligibility?"

3. "What is the primary goal of this trial—extending survival, improving quality of life, or testing a new mechanism?"

4. "How does this trial compare to standard treatment options available to me right now?"

5. "What are the inclusion/exclusion criteria, and do I definitely qualify?"

6. "What additional testing or monitoring would the trial require?"

7. "Are there any costs to me, or is treatment covered?"

8. "What happens to my care if I need to leave the trial?"

Important Considerations for Your Situation

Your Treatment History Matters:

• You've already received ADT, abiraterone, and chemotherapy
• This means trials investigating different mechanisms or novel combinations are most relevant
• Trials simply repeating treatments you've already had are less likely to help

PSA Monitoring: According to NCCN Guidelines, your PSA level and its trajectory are key indicators:

• Stable or declining PSA suggests current treatment is working
• Rising PSA would indicate need for treatment change
• Continue regular PSA monitoring (typically every 3 months for your situation)

Biomarker Testing: Before pursuing trials, ensure you've had comprehensive biomarker testing:

• BRCA1/BRCA2 status
• Microsatellite instability (MSI)
• Tumor mutational burden (TMB)
• PSMA expression (if considering PSMA-targeted trials)

Geographic Consideration

Since you're in Israel, you have access to:

• High-quality Israeli cancer centers with active research programs
• European trial networks (through geographic proximity and research partnerships)
• Potentially international trials with remote monitoring options

Your oncology team should be your primary resource for identifying which specific trials are actively enrolling in Israel and match your profile.

---

Summary

Strong Evidence Available For:

• NCCN Guidelines clearly outline treatment approaches for patients with your disease stage and treatment history
• Biomarker-driven trial selection is well-established
• Multiple trial types (immunotherapy, PSMA-targeted, novel hormone therapy) exist for advanced prostate cancer

What You Should Do Next:

1. Ask your care team: "What clinical trials are currently enrolling in Israel for patients with my specific situation?"
2. Request biomarker testing if not already completed
3. Use ClinicalTrials.gov filtered for Israel + prostate cancer
4. Contact major Israeli cancer centers directly about their active trials

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation. Your oncologist in Israel will be best positioned to identify which specific trials match your biomarkers, treatment history, and current disease status.